A Multi-Center, North American, Randomized, Double-Blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease
The Huntington Study Group (HSG) is conducting a study of the research medication ACR16 in persons 30 years of age and older who have clinical features of Huntington Disease (HD). HART is designed to determine the general safety and tolerability and an effective dose of ACR16 as well as the effect of ACR16 on motor (movement) and cognitive (thinking) abilities in subjects with HD. Approximately 35 research centers in North America will enroll up to 220 subjects for 16 weeks each. Enrollment began in October 2008. This study is sponsored by NeuroSearch Sweden AB.
Please see the HART Participating Site List. New sites will be added to this list as they secure the approval required to enroll study participants.
HART Participating Site List
HART Press Release (December 2008)
The HART study with Huntexil® shows significant effect on total motor function in patients with Huntington's disease although it did not meet the primary endpoint after 12 weeks of treatment (October 2010)
NeuroSearch presents additional data from the MermailHD Study with Huntexil® at the 5th Annual CHDI Conference on Huntington's Disease (February 2010)
NeuroSearch Reports Good Results from the European Trial ACR16 (February 2010)
Desperately Seeking 60 Good People by Dr. Lavonne Veatch Goodman (February 2010)
The European trial of ACR16 yields good results by Dr. Marsha Miller (February 2010)
HART HDTrials.org Study Listing Information (June 2009)
HART News Article by Dr. Marsha Miller (February 2009)
HART News Article by Dr. LaVonne Veatch Goodman (February 2009)
last updated: October 2010